For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ECOG-ACRIN EA6134

Trial Overview

Official Title

Testing Therapy Sequence for Advanced BRAF Mutation Melanoma

Study Purpose

To compare the good and bad effects of the sequence of immunotherapy followed by BRAF inhibitor therapy if and when it gets worse.

Diagnosis

Stage III or IV Melanoma

Eligibility

Melanoma cannot be removed by surgery.

Finished with chemotherapy, immunotherapy, or other therapy by 4 weeks or longer.

Women must not be pregnant or breast feeding.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group 1: Immunotherapy=Ipilimumab and Nivolumab and at Disease Progression BRAF Inhibitor Therapy=Dabrafenib and Trametinib
  • Group 2: BRAF Inhibitor Therapy=Dabrafenib and Trametinib and at Disease Progression Immunotherapy=Ipilimumab and Nivolumab
  • Quality of Life questionnaires

After completion of the study patients will be followed for 5 years   

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
EA6134
Related Specialties